CRL
Charles River Laboratories International, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Strong buy
+60/100
Last price
309.99
▼ 0.78 (0.25%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
315.00
Prev close
310.77
Day high
333.30
Day low
300.01
Volume
1.92M
Market cap
$14.69B
P/E (TTM)
—
52W range
146.20 – 333.30
Day trading desk
Gap from prior close
+1.36%
Prior close 310.77
VWAP
308.64
+0.44% from price
Relative volume
4.92×
Unusually busy
Session range
11.09%
300.01 – 333.30
Position in range
30%
Near session low
ATR (14D)
12.59
4.06% of price
Prior day high
312.26
PDH
Prior day low
292.02
PDL
Bid / ask spread
—
Quote not published
Session volume
4.62M
Avg 940.11K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+3.04%
+1.1%
1M
+5.71%
+4.5%
3M
+36.17%
+31.6%
6M
+79.87%
+61.7%
YTD
+52.88%
+38.6%
1Y
+71.97%
+55.6%
3Y
+55.61%
-26.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CRL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+191.74K
Net buying
Buy transactions
35
357.73K shares
Sell transactions
10
165.99K shares
Net transactions
+45
Buys less sells
Sell : buy shares
0.5 : 1
Mixed
Insider-held shares
226.28K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 25, 26 | FOSTER JAMES C Director |
SELL | 33.56K | $10.07M | Direct |
| Aug 25, 26 | FOSTER JAMES C Director |
CONVERSION | 33.56K | $6.69M | Direct |
| Aug 19, 26 | PARISOTTO SHANNON M Officer |
SELL | 2.04K | $599.71K | Direct |
| Aug 19, 26 | PARISOTTO SHANNON M Officer |
CONVERSION | 2.04K | $395.81K | Direct |
| Aug 19, 26 | GIRSHICK BIRGIT Chief Executive Officer |
STOCK | 528 | $0 | Direct |
| Aug 18, 26 | ANDREWS NANCY C Director |
SELL | 573 | $163.44K | Direct |
| Aug 18, 26 | ANDREWS NANCY C Director |
CONVERSION | 573 | $94.14K | Direct |
| Aug 11, 26 | PARISOTTO SHANNON M Officer |
SELL | 3.71K | $1.04M | Direct |
| Aug 11, 26 | PARISOTTO SHANNON M Officer |
CONVERSION | 3.71K | $667.26K | Direct |
| Aug 11, 26 | GIRSHICK BIRGIT Chief Executive Officer |
SELL | 6.50K | $1.82M | Direct |
| Aug 11, 26 | GIRSHICK BIRGIT Chief Executive Officer |
CONVERSION | 6.50K | $1.17M | Direct |
| Aug 10, 26 | FOSTER JAMES C Director |
SELL | 28.73K | $7.90M | Direct |
| Aug 10, 26 | FOSTER JAMES C Director |
CONVERSION | 28.73K | $5.16M | Direct |
| Aug 10, 26 | LAPLUME JOSEPH W Officer |
STOCK | 257 | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARBO WILLIAM D |
Officer | — | Stock Gift |
COLEMAN GLENN G |
Chief Financial Officer | 27.75K | Stock Award(Grant) |
CREAMER VICTORIA L |
Officer | 30.05K | Sale |
FOSTER JAMES C |
Director | 233.41K | Sale |
GIRSHICK BIRGIT |
Chief Executive Officer | 79.29K | Stock Gift |
LAPLUME JOSEPH W |
Officer | 31.04K | Stock Gift |
MACKAY MARTIN |
Director | 17.14K | Stock Award(Grant) |
PARISOTTO SHANNON M |
Officer | 43.00K | Sale |
PEASE FLAVIA H. |
Chief Financial Officer | 17.30K | Stock Award(Grant) |
WALLMAN RICHARD F. |
Director | — | Sale |
Fundamentals
Market cap$14.69B
Enterprise value$17.45B
Revenue (TTM)$4.00B
Gross profit$1.38B
EBITDA$849.12M
Net income$-238.46M
EPS (TTM)$-4.80
Free cash flow$468.86M
Total cash$192.02M
Total debt$3.03B
Book value / share$59.50
Shares outstanding48.17M
Float47.20M
Short % of float5.40%
Dividend yield0.00%
Beta (5Y)1.40
Valuation & profitability ratios
Trailing P/E—
Forward P/E23.94
PEG ratio0.12
Price / sales—
Price / book5.13
EV / revenue4.36
EV / EBITDA20.55
Gross margin34.59%
Operating margin15.11%
Profit margin-5.96%
Return on equity-7.52%
Return on assets4.11%
Debt / equity105.05
Current ratio1.35
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $4.02B | $4.05B | $4.13B | $3.98B | -0.9% |
| Operating revenue | $4.02B | $4.05B | $4.13B | $3.98B | -0.9% |
| Cost of revenue | $2.69B | $2.72B | $2.63B | $2.51B | -1.0% |
| Gross profit | $1.32B | $1.33B | $1.50B | $1.46B | -0.6% |
| Selling, general & admin | $743.07M | $751.00M | $747.86M | $665.10M | -1.1% |
| Total operating expense | $922.14M | $889.47M | $885.29M | $811.68M | +3.7% |
| Operating income | $401.14M | $442.35M | $617.26M | $650.98M | -9.3% |
| Net interest income | -$102.09M | -$117.71M | -$131.51M | -$58.51M | +13.3% |
| Pre-tax income | -$99.50M | $93.11M | $581.28M | $622.99M | -206.9% |
| Tax provision | $42.66M | $67.82M | $100.91M | $130.38M | -37.1% |
| Net income | -$144.34M | $10.30M | $474.62M | $486.23M | -1,501.7% |
| Net income to common | -$144.34M | $10.30M | $474.62M | $486.23M | -1,501.7% |
| Basic EPS | -2.91 | 0.20 | 9.27 | 9.57 | -1,555.0% |
| Diluted EPS | -2.91 | 0.20 | 9.22 | 9.48 | -1,555.0% |
| EBIT | $7.53M | $219.40M | $717.99M | $682.28M | -96.6% |
| EBITDA | $410.84M | $581.14M | $1.03B | $986.15M | -29.3% |
| Basic shares | 49.56M | 51.38M | 51.23M | 50.81M | -3.5% |
| Diluted shares | 49.56M | 51.63M | 51.45M | 51.30M | -4.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $213.77M | $194.61M | $276.77M | $233.91M | +9.8% |
| Cash & short-term investments | $213.77M | $194.61M | $276.77M | $233.91M | +9.8% |
| Accounts receivable | $518.73M | $527.71M | $578.08M | $559.41M | -1.7% |
| Inventory | $299.10M | $278.54M | $380.26M | $255.81M | +7.4% |
| Total current assets | $1.45B | $1.40B | $1.61B | $1.44B | +3.1% |
| Property, plant & equipment | $2.02B | $2.02B | $2.03B | $1.86B | +0.0% |
| Goodwill & intangibles | $3.10B | $3.57B | $3.96B | $3.81B | -13.0% |
| Total assets | $7.14B | $7.53B | $8.20B | $7.60B | -5.2% |
| Total current liabilities | $1.12B | $994.10M | $1.06B | $1.09B | +12.7% |
| Long-term debt | $2.11B | $2.21B | $2.65B | $2.71B | -4.6% |
| Total debt | $2.57B | $2.72B | $3.07B | $3.10B | -5.6% |
| Total liabilities | $3.92B | $4.02B | $4.54B | $4.58B | -2.4% |
| Retained earnings | $1.39B | $1.81B | $1.89B | $1.43B | -23.4% |
| Shareholder equity | $3.16B | $3.46B | $3.60B | $2.98B | -8.6% |
| Working capital | $326.73M | $408.97M | $553.58M | $347.45M | -20.1% |
| Net tangible assets | $60.38M | -$108.50M | -$362.21M | -$828.88M | +155.6% |
| Shares issued | 49.22M | 51.14M | 51.34M | 50.94M | -3.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$142.16M | $25.29M | $480.37M | $492.61M | -662.1% |
| Depreciation & amortisation | $403.31M | $361.74M | $314.12M | $303.87M | +11.5% |
| Stock-based compensation | $71.08M | $69.89M | $72.05M | $73.62M | +1.7% |
| Change in working capital | $14.08M | -$30.33M | -$102.38M | -$152.55M | +146.4% |
| Operating cash flow | $737.65M | $734.58M | $683.90M | $619.64M | +0.4% |
| Capital expenditure | -$219.15M | -$232.97M | -$318.53M | -$324.73M | +5.9% |
| Investing cash flow | -$209.32M | -$245.09M | -$563.15M | -$607.92M | +14.6% |
| Share buybacks | -$360.67M | -$119.17M | -$24.16M | -$38.65M | -202.6% |
| Financing cash flow | -$536.73M | -$550.93M | -$85.52M | -$42.40M | +2.6% |
| Free cash flow | $518.49M | $501.61M | $365.37M | $294.91M | +3.4% |
| End cash position | $216.00M | $205.57M | $284.48M | $241.21M | +5.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.00B | $995.83M | $994.23M | $1.00B | $1.03B | +0.8% |
| Operating revenue | $1.00B | $995.83M | $994.23M | $1.00B | $1.03B | +0.8% |
| Cost of revenue | $640.70M | $701.17M | $684.54M | $666.06M | $675.07M | -8.6% |
| Gross profit | $363.37M | $294.66M | $309.68M | $338.79M | $357.07M | +23.3% |
| Selling, general & admin | $228.90M | $159.42M | $196.14M | $177.59M | $191.55M | +43.6% |
| Total operating expense | $243.49M | $174.77M | $217.15M | $204.99M | $256.93M | +39.3% |
| Operating income | $119.89M | $119.90M | $92.53M | $133.80M | $100.13M | -0.0% |
| Net interest income | -$29.31M | -$25.71M | -$22.76M | -$23.98M | -$28.87M | -14.0% |
| Pre-tax income | $53.17M | -$29.94M | -$294.10M | $87.20M | $71.42M | +277.6% |
| Tax provision | $53.93M | -$15.14M | -$17.81M | $31.64M | $18.73M | +456.2% |
| Net income | -$1.48M | -$14.84M | -$276.56M | $54.42M | $52.33M | +90.0% |
| Net income to common | -$1.48M | -$14.84M | -$276.56M | $54.42M | $52.33M | +90.0% |
| Basic EPS | -0.03 | -0.30 | -5.62 | 1.11 | 1.06 | +90.0% |
| Diluted EPS | -0.03 | -0.30 | -5.62 | 1.10 | 1.06 | +90.0% |
| EBIT | $83.51M | -$3.20M | -$270.32M | $112.60M | $101.39M | +2,709.7% |
| EBITDA | $150.80M | $63.95M | -$192.05M | $197.77M | $220.89M | +135.8% |
| Basic shares | 48.02M | 48.95M | 49.22M | 49.21M | 49.15M | -1.9% |
| Diluted shares | 48.02M | 48.95M | 49.22M | 49.43M | 49.32M | -1.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $192.03M | $191.83M | $213.77M | $207.10M | $182.82M | +0.1% |
| Cash & short-term investments | $192.03M | $191.83M | $213.77M | $207.10M | $182.82M | +0.1% |
| Accounts receivable | $524.81M | $512.74M | $518.73M | $537.40M | $565.18M | +2.4% |
| Inventory | $346.26M | $359.72M | $299.10M | $302.55M | $279.55M | -3.7% |
| Total current assets | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | +2.7% |
| Property, plant & equipment | $1.83B | $1.83B | $2.02B | $1.97B | $1.99B | -0.2% |
| Goodwill & intangibles | $3.33B | $3.29B | $3.10B | $3.49B | $3.54B | +1.2% |
| Total assets | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | -2.6% |
| Total current liabilities | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | +3.8% |
| Long-term debt | $2.62B | $2.66B | $2.11B | $2.19B | $2.33B | -1.6% |
| Total debt | $3.03B | $3.06B | $2.57B | $2.63B | $2.79B | -0.9% |
| Total liabilities | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | -2.1% |
| Retained earnings | $1.37B | $1.37B | $1.39B | $1.94B | $1.89B | -0.1% |
| Shareholder equity | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | -3.4% |
| Working capital | $394.36M | $395.10M | $326.73M | $410.22M | $389.42M | -0.2% |
| Net tangible assets | -$490.39M | -$348.43M | $60.38M | -$87.93M | -$185.40M | -40.7% |
| Shares issued | 47.73M | 49.34M | 49.22M | 51.35M | 51.34M | -3.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$760.00K | -$14.80M | -$276.29M | $55.56M | $52.69M | +94.9% |
| Depreciation & amortisation | $67.29M | $67.15M | $78.28M | $85.16M | $119.51M | +0.2% |
| Stock-based compensation | $19.78M | $22.38M | $17.63M | $23.27M | $17.05M | -11.6% |
| Change in working capital | -$176.00K | -$106.08M | $6.77M | -$5.14M | $11.17M | +99.8% |
| Operating cash flow | $179.72M | — | — | — | — | — |
| Capital expenditure | -$31.11M | -$55.91M | -$88.95M | -$35.58M | -$35.30M | +44.4% |
| Investing cash flow | $28.10M | -$407.85M | -$92.81M | -$33.70M | -$37.34M | +106.9% |
| Share buybacks | -$115.60M | -$208.28M | -$96.00K | -$93.00K | -$7.35M | +44.5% |
| Financing cash flow | -$164.66M | $347.72M | -$51.86M | -$152.62M | -$226.92M | -147.4% |
| Free cash flow | $148.62M | -$14.83M | $58.57M | $178.25M | $169.31M | +1,102.1% |
| End cash position | $240.58M | $198.20M | $216.00M | $209.22M | $184.74M | +21.4% |
Options analytics
Put / call volume
0.41
Call-heavy session
Put / call open interest
10.25
Positioning, not flow
Max pain
195.00
-36.1% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
910
Contracts, this expiry
Put volume
374
Contracts, this expiry
Heaviest call OI
250.00
6 contracts
Heaviest put OI
195.00
99 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 2.74 | 3.02 | +10.3% |
| Mar 2026 | 1.95 | 2.06 | +5.4% |
| Dec 2025 | 2.35 | 2.39 | +1.9% |
| Sep 2025 | 2.34 | 2.43 | +3.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 2.97 | 13 | $960.34M | -4.4% |
| Next quarter | 3.32 | 13 | $955.23M | -3.9% |
| Current year | 11.35 | 17 | $3.92B | -2.4% |
| Next year | 12.74 | 17 | $4.01B | +2.3% |
Analyst targets & ownership
Mean target$305.00
High target$357.00
Low target$145.00
Implied upside-1.61%
Analyst count15
ConsensusBUY
Strong buy / Buy4 / 11
Hold2
Sell / Strong sell1 / 0
Held by insiders0.47%
Held by institutions122.91%
Institutions holding801
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
294.29
+5.33% from price
SMA 20
285.79
+6.71% from price
SMA 50
279.36
+9.16% from price
SMA 100
238.64
+29.90% from price
SMA 200
211.09
+44.47% from price
EMA 12
293.82
+5.50% from price
EMA 26
287.31
+7.89% from price
EMA 50
274.58
+12.90% from price
RSI (14)
62.2
Neutral
MACD (12,26,9)
6.51
Hist 1.51
ATR (14)
12.59
4.13% of price
Realised vol 30D
36.9%
Annualised
Bollinger upper
307.48
20, 2σ
Bollinger lower
264.09
20, 2σ
50 / 200 cross
Golden
279.36 vs 211.09
Trend bias
Above 200
+44.47%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.24
More volatile than market
Correlation to SPY
0.36
Loosely linked
Realised vol 30D
36.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-33.9%
Peak to trough
Max drawdown 5Y
-77.8%
Peak to trough
ATR 14
12.59
4.13% of price
Beta (reported)
1.40
5Y monthly, from filing
Short interest
Shares short
2.23M
Prior 2.36M
Change vs prior
-5.5%
Shorts covering
% of float
5.40%
Normal
% of shares out
4.67%
Against total outstanding
Days to cover
2.6
Liquid
Float
47.20M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 28, 26 | Jefferies | MAINTAINED | Buy | Buy |
| Sep 25, 26 | Deutsche Bank | MAINTAINED | Buy | Buy |
| Sep 25, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Sep 25, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Sep 25, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Sep 25, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Sep 25, 26 | Mizuho | MAINTAINED | Neutral | Neutral |
| Sep 25, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Sep 11, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Aug 10, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 7, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Aug 6, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-24
Periodic Financial Reports
10-Q · 2026-08-05
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-11
Corporate Changes & Voting Matters
8-K · 2026-05-07
Annual Report to Shareholders
ARS · 2026-03-31
Corporate Changes & Voting Matters
8-K · 2026-02-25
Periodic Financial Reports
10-K · 2026-02-18
Corporate Changes & Voting Matters
8-K · 2026-01-13
Headlines
Is It Prudent to Add Teleflex Stock to Your Portfolio Now?
Zacks · 15h ago
Charles River and Autolomous Partner to Transform Laboratory Execution Systems
Business Wire · 17h ago
Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases
Simply Wall St. · 4d ago
Animal Model - Global Strategic Business Report: Market Size to Surge to $3.6 Billion by 2032 as CRISPR Disrupts R&D - Benchmark Charles River, Biocytogen, Crown Bioscience, Cyagen and The Jackson Laboratory
GlobeNewswire · 7d ago
UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175
MT Newswires · 7d ago
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?
Zacks · 7d ago
Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery
Insider Monkey · 8d ago
Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River
GlobeNewswire · 8d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.